New drug cocktail shows promise for bladder cancer patients
NCT ID NCT04386746
First seen Nov 17, 2025 · Last updated May 09, 2026 · Updated 22 times
Summary
This study tests a combination of two chemotherapy drugs, gemcitabine and docetaxel, given directly into the bladder for people with early-stage bladder cancer who have not received standard BCG therapy. The goal is to see if this treatment can clear the cancer and keep it from coming back. 27 participants will be followed for up to 2 years to measure response and relapse rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.